Boostertx

3 known investors

Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools. The company is building a multi-disease pipeline initially focused on neurodegenerative diseases.